Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TNDM Tandem Diabetes Care Inc
- Stocks
- Healthcare
- NASDAQ: TNDM
Price (delayed)
$23.08
Market cap
$1.54B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.78
Enterprise value
$1.98B
Tandem Diabetes Care is a public US medical device manufacturer based in San Diego, CA. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
Highlights
Tandem Diabetes Care's gross profit has increased by 35% YoY and by 4.8% from the previous quarter
TNDM's revenue is up by 28% year-on-year and by 4.5% since the previous quarter
The net income has plunged by 91% from the previous quarter and by 30% YoY
Tandem Diabetes Care's EPS has plunged by 89% from the previous quarter and by 28% YoY
Key stats
What are the main financial stats of TNDM
Market
Valuations
Earnings
Shares outstanding
66.61M
Market cap
$1.54B
Enterprise value
$1.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.88
Price to sales (P/S)
1.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.01
Revenue
$982.95M
Gross profit
$513.31M
Operating income
-$178.33M
Net income
-$183.87M
EBIT
-$167.05M
EBITDA
-$150.18M
Free cash flow
-$3.8M
Per share
Balance sheet
Liquidity
EPS
-$2.78
EPS diluted
-$2.78
Free cash flow per share
-$0.06
Book value per share
$2.34
Revenue per share
$14.8
TBVPS
$13.89
Total assets
$922.14M
Total liabilities
$766.85M
Debt
$493.2M
Equity
$155.29M
Working capital
$375.26M
Debt to equity
3.18
Current ratio
2.3
Quick ratio
1.72
Net debt/EBITDA
-2.93
Margins
Efficiency
Dividend
EBITDA margin
-15.3%
Gross margin
52.2%
Net margin
-18.7%
Operating margin
-18.1%
Return on assets
-19.4%
Return on equity
-82.6%
Return on invested capital
-15%
Return on capital employed
-26.3%
Return on sales
-17%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNDM stock price
How has the Tandem Diabetes Care stock price performed over time
Intraday
1.67%
1 week
0.44%
1 month
33.72%
1 year
-50.82%
YTD
-35.92%
QTD
20.46%
Financial performance
How have Tandem Diabetes Care's revenue and profit performed over time
Revenue
$982.95M
Gross profit
$513.31M
Operating income
-$178.33M
Net income
-$183.87M
Gross margin
52.2%
Net margin
-18.7%
The net income has plunged by 91% from the previous quarter and by 30% YoY
The net margin has plunged by 83% from the previous quarter
The operating income has shrunk by 80% QoQ and by 21% YoY
The operating margin has plunged by 72% from the previous quarter but it has grown by 5% YoY
Price vs fundamentals
How does TNDM's price correlate with its fundamentals
Growth
What is Tandem Diabetes Care's growth rate over time
Valuation
What is Tandem Diabetes Care stock price valuation
P/E
N/A
P/B
9.88
P/S
1.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.01
Tandem Diabetes Care's EPS has plunged by 89% from the previous quarter and by 28% YoY
The company's equity fell by 41% QoQ and by 36% YoY
TNDM's price to book (P/B) is 20% less than its 5-year quarterly average of 12.4
The P/S is 76% lower than the 5-year quarterly average of 6.6 and 40% lower than the last 4 quarters average of 2.6
TNDM's revenue is up by 28% year-on-year and by 4.5% since the previous quarter
Efficiency
How efficient is Tandem Diabetes Care business performance
TNDM's ROE has plunged by 110% from the previous quarter and by 75% YoY
The return on invested capital has dropped by 103% since the previous quarter and by 32% year-on-year
The return on assets has dropped by 92% since the previous quarter and by 29% year-on-year
Tandem Diabetes Care's ROS has plunged by 89% from the previous quarter and by 3.7% YoY
Dividends
What is TNDM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNDM.
Financial health
How did Tandem Diabetes Care financials performed over time
The total assets is 20% greater than the total liabilities
Tandem Diabetes Care's quick ratio has decreased by 41% YoY and by 23% from the previous quarter
TNDM's current ratio is down by 40% year-on-year and by 22% since the previous quarter
The company's debt to equity has surged by 77% QoQ and by 62% YoY
The company's equity fell by 41% QoQ and by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.